News & Media / Press Releases

John Nolan Joins WBB to Head Asset Management Team

September 2, 2016

WBB Securities, a leading investment management, investment banking, and equity research firm, announced today that John Nolan has joined the firm as Managing Director of WBB Asset Management[1] where he will also serve as a Portfolio Manager of a concentrated long/short portfolio that focuses on the biotechnology, specialty pharmaceutical and medical device sectors.

Continue Reading

WBB Securities Sponsors BioCentury’s Annual NewsMakers Conference

September 1, 2016

WBB Securities is a sponsor of this year’s NewsMakers in the Biotech Industry conference.

Continue Reading

How Mylan And Pfizer Could Cause A Major Biotech Backlash

August 25, 2016

You know you’re in the middle of a crisis when Martin Shkreli defends your pharmaceutical company’s price hikes.

Continue Reading

Brexit Will Be Bad For Pharma

June 25, 2016

In medicine they talk about triage in making quick decisions to save lives. Central bankers and politicians across Europe will be performing financial triage this weekend on the UK and EU.

Continue Reading

Superbug Hearing: Will Congress Pick Up Ali’s Fight Against Sepsis?

June 14, 2016

During his life, Muhammad Ali did many great things for a great many people. But he may still have another contribution to make to the public, or in this case, for the public’s health.

Continue Reading

A Simple Solution To Fixing The Prescription Drug Cost Crisis

June 6, 2016

The U.S. healthcare system isn’t sustainable in its current form with increasing prices, and the disparate approaches to care across states, hospitals, doctors, insurance companies, and income.

Continue Reading

As Sarepta And Valeant Exit Hearings, Biotech Steps Into M&A

May 2, 2016

The last week was a nonstop whirlwind for biotech, so I’ve decided to treat this entry a little differently by commenting on key events and sharing what I’ve been seeing.

Continue Reading

What Weak Earnings At Goldman Sachs And J.P. Morgan Mean For Biotech

April 22, 2016

This week Goldman Sachs announced that its profits fell 60% in a single quarter and blamed a volatile market that’s hit it across business lines.

Continue Reading

Theranos Debacle May Scare Investors Away From Diagnostic Technology

April 13, 2016

Now that Theranos faces the prospect of a crippling ban on its operations by federal officials, let’s get past its implosion and talk about the real implications for the rest of the diagnostic sector.

Continue Reading

Why Valeant Should Be Broken Up

March 17, 2016

It’s not often that we see the collapse of a large pharmaceutical company in real time.

Continue Reading